Piyushkumar A. Mundra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Piyushkumar A. Mundra has a total of 305 co-authors. Here are the top co-authors by number of shared publications:
- Peter J. Meikle
Baker Heart and Diabetes Institute
21 shared publications - Jagath Chandana Rajapakse
Nanyang Technological University
13 shared publications Gerard Wong
Baker Heart and Diabetes Institute, Melbourne, Australia
8 shared publicationsNatalie A. Mellett
Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
7 shared publications- Richard Marais
Cancer Research UK Manchester Institute, Manchester, UK
7 shared publications Jacquelyn M. Weir
6 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Springer Nature in BMC Bioinformatics
Modality-aware external attention with explicit cross-omics interaction modelling for breast cancer subtype classification
- 3 November 2026
- Published by Springer Nature in BMC Bioinformatics
Open AccessModality-aware external attention with explicit cross-omics interaction modelling for breast cancer subtype classification
- Open Access
- 28 September 2024
- Published by Elsevier in Genetics in Medicine Open
- Vol. 2, 101895
Increased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans
- 28 September 2024
- Published by Elsevier in Genetics in Medicine Open
- Vol. 2, 101895
Open AccessIncreased frequency of CHEK2 germline pathogenic variants among individuals with dermatofibrosarcoma protuberans
- 20 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 379 (6629) , 253-260
Heritable defects in telomere and mitotic function selectively predispose to sarcomas
Cancer genetics has to date focused on epithelial malignancies, identifying multiple histotype-specific pathways underlying cancer susceptibility. Sarcomas are rare malignancies predominantly derived from embryonic mesoderm. To identify pathways specific to mesenchymal cancers, we performed whole-genome germline sequencing on 1644 sporadic cases and 3205 matched healthy elderly controls. Using an extreme phenotype design, a combined rare-variant burden and ontologic analysis identified two sarcoma-specific pathways involved in mitotic and telomere functions. Variants in centrosome genes are linked to malignant peripheral nerve sheath and gastrointestinal stromal tumors, whereas heritable defects in the shelterin complex link susceptibility to sarcoma, melanoma, and thyroid cancers. These studies indicate a specific role for heritable defects in mitotic and telomere biology in risk of sarcomas.
- 20 January 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 379 (6629) , 253-260
Heritable defects in telomere and mitotic function selectively predispose to sarcomas
Cancer genetics has to date focused on epithelial malignancies, identifying multiple histotype-specific pathways underlying cancer susceptibility. Sarcomas are rare malignancies predominantly derived from embryonic mesoderm. To identify pathways specific to mesenchymal cancers, we performed whole-genome germline sequencing on 1644 sporadic cases and 3205 matched healthy elderly controls. Using an extreme phenotype design, a combined rare-variant burden and ontologic analysis identified two sarcoma-specific pathways involved in mitotic and telomere functions. Variants in centrosome genes are linked to malignant peripheral nerve sheath and gastrointestinal stromal tumors, whereas heritable defects in the shelterin complex link susceptibility to sarcoma, melanoma, and thyroid cancers. These studies indicate a specific role for heritable defects in mitotic and telomere biology in risk of sarcomas.
- Open Access
- 2 June 2021
- Published by Springer Nature in BMC Bioinformatics
- Vol. 22 (S6) , 1-16
PIKE-R2P: Protein–protein interaction network-based knowledge embedding with graph neural network for single-cell RNA to protein prediction
Background: Recent advances in simultaneous measurement of RNA and protein abundances at single-cell level provide a unique opportunity to predict protein abundance from scRNA-seq data using machine learning models. However, existing machine learning methods have not considered relationship among the proteins sufficiently. Results: We formulate this task in a multi-label prediction framework where multiple proteins are linked to each other at the single-cell level. Then, we propose a novel method for single-cell RNA to protein prediction named PIKE-R2P, which incorporates protein–protein interactions (PPI) and prior knowledge embedding into a graph neural network. Compared with existing methods, PIKE-R2P could significantly improve prediction performance in terms of smaller errors and higher correlations with the gold standard measurements. Conclusion: The superior performance of PIKE-R2P indicates that adding the prior knowledge of PPI to graph neural networks can be a powerful strategy for cross-modality prediction of protein abundances at the single-cell level.
- 2 June 2021
- Published by Springer Nature in BMC Bioinformatics
- Vol. 22 (S6) , 1-16
Open AccessPIKE-R2P: Protein–protein interaction network-based knowledge embedding with graph neural network for single-cell RNA to protein prediction
Background: Recent advances in simultaneous measurement of RNA and protein abundances at single-cell level provide a unique opportunity to predict protein abundance from scRNA-seq data using machine learning models. However, existing machine learning methods have not considered relationship among the proteins sufficiently. Results: We formulate this task in a multi-label prediction framework where multiple proteins are linked to each other at the single-cell level. Then, we propose a novel method for single-cell RNA to protein prediction named PIKE-R2P, which incorporates protein–protein interactions (PPI) and prior knowledge embedding into a graph neural network. Compared with existing methods, PIKE-R2P could significantly improve prediction performance in terms of smaller errors and higher correlations with the gold standard measurements. Conclusion: The superior performance of PIKE-R2P indicates that adding the prior knowledge of PPI to graph neural networks can be a powerful strategy for cross-modality prediction of protein abundances at the single-cell level.
- Open Access
- 11 January 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-7
Ultraviolet radiation drives mutations in a subset of mucosal melanomas
Although identified as the key environmental driver of common cutaneous melanoma, the role of ultraviolet radiation (UVR)-induced DNA damage in mucosal melanoma is poorly defined. We analyze 10 mucosal melanomas of conjunctival origin by whole genome sequencing and our data shows a predominance of UVR-associated single base substitution signature 7 (SBS7) in the majority of the samples. Our data shows mucosal melanomas with SBS7 dominance have similar genomic patterns to cutaneous melanomas and therefore this subset should not be excluded from treatments currently used for common cutaneous melanoma.
- 11 January 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-7
Open AccessUltraviolet radiation drives mutations in a subset of mucosal melanomas
Although identified as the key environmental driver of common cutaneous melanoma, the role of ultraviolet radiation (UVR)-induced DNA damage in mucosal melanoma is poorly defined. We analyze 10 mucosal melanomas of conjunctival origin by whole genome sequencing and our data shows a predominance of UVR-associated single base substitution signature 7 (SBS7) in the majority of the samples. Our data shows mucosal melanomas with SBS7 dominance have similar genomic patterns to cutaneous melanomas and therefore this subset should not be excluded from treatments currently used for common cutaneous melanoma.
- 1 January 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (1) , 221-225.e6
Map3k1 Loss Cooperates with Braf to Drive Melanomagenesis
- 1 January 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (1) , 221-225.e6
Map3k1 Loss Cooperates with Braf to Drive Melanomagenesis
- Open Access
- 12 February 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-9
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
Although immune checkpoint inhibitors (ICIs) have achieved unprecedented results in melanoma, the biological features of the durable responses initiated by these drugs remain unknown. Here we show the genetic and phenotypic changes induced by treatment with programmed cell death-1 (PD-1) blockade in a genetically engineered mouse model of melanoma driven by oncogenic BRAF. In this controlled system anti-PD-1 treatment yields responses in ~35% of the tumors, and prolongs survival in ~27% of the animals. We identify increased stroma remodeling and reduced expression of proliferation markers as features associated with prolonged response. These traits are corroborated in two independent early on-treatment anti-PD-1 melanoma patient cohorts. These insights into the biological responses of tumors to ICI provide a strategy for identification of durable response early during the course of treatment and could improve patient stratification for checkpoint inhibitory drugs.
- 12 February 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-9
Open AccessStroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma
Although immune checkpoint inhibitors (ICIs) have achieved unprecedented results in melanoma, the biological features of the durable responses initiated by these drugs remain unknown. Here we show the genetic and phenotypic changes induced by treatment with programmed cell death-1 (PD-1) blockade in a genetically engineered mouse model of melanoma driven by oncogenic BRAF. In this controlled system anti-PD-1 treatment yields responses in ~35% of the tumors, and prolongs survival in ~27% of the animals. We identify increased stroma remodeling and reduced expression of proliferation markers as features associated with prolonged response. These traits are corroborated in two independent early on-treatment anti-PD-1 melanoma patient cohorts. These insights into the biological responses of tumors to ICI provide a strategy for identification of durable response early during the course of treatment and could improve patient stratification for checkpoint inhibitory drugs.
- 10 February 2020
- Published by Springer Nature in Nature Cancer
- Vol. 1 (2) , 210-221
Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy
Our understanding of how checkpoint inhibitors (CPIs) affect T cell evolution is incomplete, limiting our ability to achieve full clinical benefit from these drugs. Here, we analyzed peripheral T cell populations after one cycle of CPI treatment and identified a dynamic awakening of the immune system, as revealed by T cell evolution in response to treatment. We sequenced T cell receptors in plasma cell-free DNA and peripheral blood mononuclear cells and performed phenotypic analysis of peripheral T cell subsets from patients with metastatic melanoma treated with CPIs. We found that early peripheral T cell turnover and T cell receptor repertoire dynamics identified which patients would respond to treatment. Additionally, the expansion of a subset of immune effector peripheral T cells we call TIE cells correlated with response. These events are prognostic and occur within 3 weeks of starting immunotherapy, raising the potential for monitoring patients’ responses by using minimally invasive liquid biopsies.
- 10 February 2020
- Published by Springer Nature in Nature Cancer
- Vol. 1 (2) , 210-221
Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy
Our understanding of how checkpoint inhibitors (CPIs) affect T cell evolution is incomplete, limiting our ability to achieve full clinical benefit from these drugs. Here, we analyzed peripheral T cell populations after one cycle of CPI treatment and identified a dynamic awakening of the immune system, as revealed by T cell evolution in response to treatment. We sequenced T cell receptors in plasma cell-free DNA and peripheral blood mononuclear cells and performed phenotypic analysis of peripheral T cell subsets from patients with metastatic melanoma treated with CPIs. We found that early peripheral T cell turnover and T cell receptor repertoire dynamics identified which patients would respond to treatment. Additionally, the expansion of a subset of immune effector peripheral T cells we call TIE cells correlated with response. These events are prognostic and occur within 3 weeks of starting immunotherapy, raising the potential for monitoring patients’ responses by using minimally invasive liquid biopsies.
- Open Access
- 11 July 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (13)
Changes in plasma lipids predict pravastatin efficacy in secondary prevention
BACKGROUND: Statins have pleiotropic effects on lipid metabolism. The relationship between these effects and future cardiovascular events is unknown. We characterized the changes in lipids upon pravastatin treatment and defined the relationship with risk reduction for future cardiovascular events. METHODS: Plasma lipids ( n = 342) were measured in baseline and 1-year follow-up samples from a Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study subcohort ( n = 4991). The associations of changes in lipids with treatment and cardiovascular outcomes were investigated using linear and Cox regression. The effect of treatment on future cardiovascular outcomes was examined by the relative risk reduction (RRR). RESULTS: Pravastatin treatment was associated with changes in 206 lipids. Species containing arachidonic acid were positively associated while phosphatidylinositol species were negatively associated with pravastatin treatment. The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6% after adjustment for clinical risk factors and change in LDL-cholesterol (LDL-C) and to 3.0% after further adjustment for the change in the lipid ratio PI(36:2)/PC(38:4). Change in PI(36:2)/PC(38:4) mediated 58% of the treatment effect. Stratification of patients into quartiles of change in PI(36:2)/PC(38:4) indicated no benefit of pravastatin in the fourth quartile. CONCLUSION: The change in PI(36:2)/PC(38:4) predicted benefit from pravastatin, independent of change in LDL-C, demonstrating its potential as a biomarker for monitoring the clinical benefit of statin treatment in secondary prevention. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry identifier ACTRN12616000535471. FUNDING: Bristol-Myers Squibb; NHMRC grants 211086, 358395, and 1029754; NHMRC program grant 1149987; NHMRC fellowship 108026; and the Operational Infrastructure Support Program of the Victorian government of Australia.
- 11 July 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (13)
Open AccessChanges in plasma lipids predict pravastatin efficacy in secondary prevention
BACKGROUND: Statins have pleiotropic effects on lipid metabolism. The relationship between these effects and future cardiovascular events is unknown. We characterized the changes in lipids upon pravastatin treatment and defined the relationship with risk reduction for future cardiovascular events. METHODS: Plasma lipids ( n = 342) were measured in baseline and 1-year follow-up samples from a Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study subcohort ( n = 4991). The associations of changes in lipids with treatment and cardiovascular outcomes were investigated using linear and Cox regression. The effect of treatment on future cardiovascular outcomes was examined by the relative risk reduction (RRR). RESULTS: Pravastatin treatment was associated with changes in 206 lipids. Species containing arachidonic acid were positively associated while phosphatidylinositol species were negatively associated with pravastatin treatment. The RRR from pravastatin treatment for cardiovascular events decreased from 23.5% to 16.6% after adjustment for clinical risk factors and change in LDL-cholesterol (LDL-C) and to 3.0% after further adjustment for the change in the lipid ratio PI(36:2)/PC(38:4). Change in PI(36:2)/PC(38:4) mediated 58% of the treatment effect. Stratification of patients into quartiles of change in PI(36:2)/PC(38:4) indicated no benefit of pravastatin in the fourth quartile. CONCLUSION: The change in PI(36:2)/PC(38:4) predicted benefit from pravastatin, independent of change in LDL-C, demonstrating its potential as a biomarker for monitoring the clinical benefit of statin treatment in secondary prevention. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry identifier ACTRN12616000535471. FUNDING: Bristol-Myers Squibb; NHMRC grants 211086, 358395, and 1029754; NHMRC program grant 1149987; NHMRC fellowship 108026; and the Operational Infrastructure Support Program of the Victorian government of Australia.
- 18 December 2018
- Published by Springer Nature in Nature Medicine
- Vol. 25 (2) , 350
Publisher Correction: Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma
In the version of this article originally published, Extended Data Fig. 3 was incorrect. A duplicate of Extended Data Fig. 4 was uploaded in place of Extended Data Fig. 3. Extended Data Fig. 3 has now been uploaded. The error has been fixed in the PDF and HTML versions of this article.
- 18 December 2018
- Published by Springer Nature in Nature Medicine
- Vol. 25 (2) , 350
Publisher Correction: Ultraviolet radiation–induced DNA damage is prognostic for outcome in melanoma
In the version of this article originally published, Extended Data Fig. 3 was incorrect. A duplicate of Extended Data Fig. 4 was uploaded in place of Extended Data Fig. 3. Extended Data Fig. 3 has now been uploaded. The error has been fixed in the PDF and HTML versions of this article.